scholarly journals Factors associated with poor outcome in fetuses prenatally diagnosed with sacrococcygeal teratoma

2021 ◽  
Author(s):  
LJ van Heurn ◽  
ABC Coumans ◽  
JPM Derikx ◽  
MN Bekker ◽  
CM Bilardo ◽  
...  
Keyword(s):  
Sacrococcygeal Teratoma ◽  
Factors Associated ◽  
Poor Outcome

P112 Management and outcome of subarachnoid haemorrhage (SAH) in older people: a centre series

2019 ◽  
Vol 90 (3) ◽  
pp. e51.3-e50
Author(s):  
T Boumrah ◽  
J Fahmy ◽  
S Trippier ◽  
A Hainsworth ◽  
J Madigan ◽  
...  
Keyword(s):  
Rank Order ◽  
External Ventricular Drain ◽  
Intraventricular Haemorrhage ◽  
Medical Complications ◽  
Motor Score ◽  
Head Ct ◽  
Factors Associated ◽  
Poor Outcome ◽  
Poor Outcome Group ◽  
Outcome Group

ObjectivesTo study the management and factors associated with outcomes in SAH in elderly over 80 years of age.DesignRetrospective records review.SubjectsAll Patients with SAH confirmed on head CT admitted Jan 2012-Dec 2017.MethodsWe admitted 1079 patients with SAH, 32 were aged ≥80 y (3%). We subdivided the patients into a poor outcome group (POG) (Modified Rankin Scale (mRS) 4–6), (n=24, 14F/10M, mean age 83.7±0.7 y) and good outcome group (GOG) (mRS 0–3) (n=8, 7F/1M, mean age 82.6±0.6 y). Spearman’s rank-order test evaluated correlation between outcome (mRS) and all other variables (WFNS grade, GCS, Motor score of GCS, age, sex, smoking, hypertension, intraventricular haemorrhage (IVH) and intracerebral haemorrhages (ICH)).Results9 patients (38%) of POG were WFNS grades IV – V versus 1 patient (13%) in GOG. More POG than GOG patients had IVH (83% vs 38%, rs=−0.44 p=0.011). 20% of POG had ICH vs none in GOG. GOG patients had better GCS (rs=−0.37, p=0.04), lower WFNS grade (rs=0.43, p=0.01) and did not need external ventricular drain (EVD) (rs=0.51, p=0.003). There was no significant correlation between outcome and sex, smoking, hypertension, size of aneurysm (4.9 mm ±1.0 in GOG vs 5.4 mm ±1.1 in POG, rs=−0.29, p=0.28), percentage receiving coiling or clipping, GCS motor score, procedure complications and general medical complications.Conclusions75% of patients’ aged ≥80 y with SAH had poor outcome. WFNS grade (I-III), higher GCS patients who did not need EVD had better outcome.

Factors Associated With Poor Outcome in Pediatric Near-Hanging Injuries

2019 ◽  
Vol 57 (1) ◽  
pp. 21-28
Author(s):  
Stephanie La Count ◽  
Marlina E. Lovett ◽  
Songzhu Zhao ◽  
David Kline ◽  
Nicole F. O’Brien ◽  
...  
Keyword(s):  
Factors Associated ◽  
Poor Outcome

Characteristics of intrahousehold interdog aggression and dog and pair factors associated with a poor outcome

2020 ◽  
Vol 256 (3) ◽  
pp. 349-361
Author(s):  
Elizabeth S. M. Feltes ◽  
Jason W. Stull ◽  
Meghan E. Herron ◽  
Lore I. Haug
Keyword(s):  
Factors Associated ◽  
Poor Outcome

Study of the factors associated with recurrence in children with sacrococcygeal teratoma

2006 ◽  
Vol 41 (1) ◽  
pp. 173-181 ◽  
Author(s):  
Antoine De Backer ◽  
Gerard C. Madern ◽  
Friederike G.A.J. Hakvoort-Cammel ◽  
Patrick Haentjens ◽  
J.Wolter Oosterhuis ◽  
...  
Keyword(s):  
Sacrococcygeal Teratoma ◽  
Factors Associated

Clinical Profile and Factors Associated with a Poor Outcome in Childhood Tuberculous Meningitis in a Developing Country: A 10 Year Case Review

2017 ◽  
Vol 21 (3) ◽  
pp. 1-10
Author(s):  
Loukia Aketi ◽  
Joseph Diayisu ◽  
Pierre Tshibassu ◽  
Adolphine Nkwadiolandu ◽  
Zacharie Kashongwe ◽  
...  
Keyword(s):  
Developing Country ◽  
Tuberculous Meningitis ◽  
Clinical Profile ◽  
Case Review ◽  
Factors Associated ◽  
Poor Outcome

Clinical data and factors associated with poor outcome in pneumococcal meningitis

2005 ◽  
Vol 165 (5) ◽  
pp. 285-289 ◽  
Author(s):  
Juan Casado-Flores ◽  
◽  
Javier Aristegui ◽  
Carlos Rodrigo de Liria ◽  
Jose María Martinón ◽  
...  
Keyword(s):  
Clinical Data ◽  
Pneumococcal Meningitis ◽  
Factors Associated ◽  
Poor Outcome

Short Progression Free Survival Predicts for Poor Overall Survival In Older Patients with Multiple Myeloma Treated Upfront with Novel Agent-Based Therapy

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3035-3035
Author(s):  
Efstathios Kastritis ◽  
Maria Roussou ◽  
Maria Gavriatopoulou ◽  
Magdalini Migkou ◽  
Maria Gkotzamanidou ◽  
...  
Keyword(s):  
Univariate Analysis ◽  
Fold Increase ◽  
Novel Agents ◽  
Agent Based ◽  
Early Relapse ◽  
Factors Associated ◽  
Platelet Counts ◽  
Poor Outcome ◽  
Depth Of Response ◽  
Novel Agent

Abstract Abstract 3035 Data from patients with multiple myeloma (MM) treated with autologous transplantation indicate that a short remission period after high dose therapy, usually less than 12 months, is associated with a poor outcome and limited efficacy of salvage regimens. Also, failure to respond to upfront thalidomide or lenalidomide based-regimens is associated with poor outcome. However, such data are limited for the general, unselected population of elderly or non-transplant treated MM patients, especially after the introduction of novel agents in the upfront treatment of myeloma. Thus, we analyzed the outcome of 115 unselected patients, who were older than 65 years and who were treated upfront with novel agent-based regimens in a single center in Athens, Greece. Many of these patients had been included in clinical trials; however, several patients who were ineligible because of poor performance status, significant renal impairment or comorbidities were also treated with novel agent-based regimens. Thus, these patients are more representative of the general myeloma population. IMWG criteria were used for the assessment of response, progression-free (PFS) and overall survival (OS). Forty three percent of patients were >75 years. Nine percent died within 3 months from initiation of treatment. Among 106 patients who survived for at least 3 months, 77% achieved an objective response: 20% achieved a CR, 26% a VGPR and 33% a PR. On an intention to treat, 58% of patients have progressed so far. Among patients who responded to initial treatment, 19% who had achieved a CR, 27% who had achieved a VGPR and 37% who had achieved a PR, relapsed(p=0.012). At the time of relapse or progression, patients were treated again with novel agents. Median PFS for all patients was 21 months (95% CI: 18–23 months), while median PFS for patients who achieved CR/VGPR or PR as best response was 20 months and 22 months, respectively (p=0.9). Subsequently, we analyzed 94 patients who started treatment at least 12 months before this analysis. Among these patients, 32% had a PFS shorter than 12 months including 26% of patients who initially responded. Depth of response was predictive of probability for early relapse: CR 5%, VGPR 29% and PR 38% (p=0.04). In the univariate analysis, LDH ≥300 IU/L (upper limit of normal 225 IU/L) was the only factor associated with shorter PFS while other factors such as ISS stage, age >75 years, Hb <10 g/dl, platelet counts <130,000/ml) did not affect PFS. The probability for two-year OS for patients who achieved a CR was 93%, for patients with VGPR was 69% and for patients who achieved a PR was 83% (p=0.188). Baseline factors associated with poor OS in the univariate analysis, included age >75 years (median OS of 28 months vs. 62 for patients younger than 75 years, p<0.001), hemoglobin <10 g/dl (p=0.05), platelet counts <130,000/ml (p=0.012), ISS stage (p=0.031) and elevated LDH (p<0.001). Furthermore, patients who relapsed or progressed within the first 12 months had a median survival of 18 months compared to a median survival of 53 months for patients who relapsed after at least 12 months from treatment initiation (p<0.001). In the multivariate analysis, PFS <12 months was the most significant adverse prognostic factor associated with a 12.7 (95% CI 5–33) fold increase in the risk for death. Other factors associated with poor survival were elevated LDH ≥300 IU/L (HR=10.7, p=0.001), age >75 years (HR=5.37, p<0.001), baseline platelet counts <130,000/ml (HR=4.65, p=0.001) and ISS-3 (HR=3, p=0.007). In conclusion, in elderly patients (‘65 years) who are treated upfront with novel agents, short PFS (less than 12 months) is associated with a very poor outcome and a more than 12 –fold increase in the hazard of death. Probably due to the limited number of patients, we did not observe a statistically significant correlation of the depth of response with OS. However, a significantly lower percentage of patients who had achieved a CR experienced an early relapse. Our data indicate that salvage treatments for patients who fail to respond or progress early after frontline therapy with novel agent-based regimens may not be effective and new drugs and treatment strategies are needed. These patients should be encouraged to participate in clinical trials which investigate experimental agents and combinations. Disclosures: Dimopoulos: Ortho-Biotech: Honoraria; Celgene: Honoraria; Millennium: Honoraria.

Factors Associated with Poor Outcome in Alcoholic Hepatitis and Comparison of Various Prognostic Models

2009 ◽  
Vol 104 ◽  
pp. S138
Author(s):  
Prabha Sawant ◽  
Srinivas Mallasandra Govindraj ◽  
Amol Samarth ◽  
Satheesh Rao ◽  
Chitranshu Vashishtha
Keyword(s):  
Alcoholic Hepatitis ◽  
Prognostic Models ◽  
Factors Associated ◽  
Poor Outcome
Sign in / Sign up

Export Citation Format

Share Document